Biogen (BIIB) Cash from Operations (2009 - 2026)

Biogen (BIIB) has reported Cash from Operations for 18 consecutive years, with 645500000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Operations rose 148.94% year-over-year to 645500000.0; the TTM figure through Mar 2026 stood at 2590800000.0 (changed 0.36% YoY), while the FY2025 annual figure was 2204600000.0, down 23.33% from the prior year.
• Cash from Operations came in at 645500000.0 for Q1 2026 at Biogen, up from 511900000.0 in the prior quarter.
• The five-year high for Cash from Operations was 1272500000.0 in Q3 2025, with the low at 175000000.0 in Q4 2022.
• Average Cash from Operations over 5 years is 509241176.47, with a median of 553200000.0 recorded in 2024.
• Across the five-year window, Cash from Operations tumbled 120.88% in 2022 and soared 5987.2% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 175000000.0 in 2022, then surged by 107.14% to 12500000.0 in 2023, then jumped by 5987.2% to 760900000.0 in 2024, then tumbled by 32.72% to 511900000.0 in 2025, then advanced by 26.1% to 645500000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 645500000.0, 511900000.0, and 1272500000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.